Cover Image
市場調查報告書

SymBio Pharmaceuticals Limited :產品平台分析

SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 199810
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
SymBio Pharmaceuticals Limited :產品平台分析 SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014
出版日期: 2014年12月15日 內容資訊: 英文 33 Pages
簡介

SymBio Pharmaceuticals Limited 是從事新藥劑候補的研究開發及製造的生物製藥公司。該公司主要在開發為治療化療引發的噁心嘔吐,含有Granisetron的經皮貼布等藥物遞送產品。該公司的治藥用於自體免疫疾病、腫瘤、血液障礙等領域。

本報告提供SymBio Pharmaceuticals Limited 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,以及最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

SymBio Pharmaceuticals Limited的基本資料

SymBio Pharmaceuticals Limited概要

  • 主要資訊
  • 企業資料

SymBio Pharmaceuticals Limited:R&D概要

  • 主要的治療範圍

SymBio Pharmaceuticals Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

SymBio Pharmaceuticals Limited:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

SymBio Pharmaceuticals Limited:藥物簡介

  • bendamustine hydrochloride
  • rigosertib sodium
  • SyB-0702

SymBio Pharmaceuticals Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

SymBio Pharmaceuticals Limited:最近的開發平台趨勢

SymBio Pharmaceuticals Limited:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • forigerimod

SymBio Pharmaceuticals Limited:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06661CDB

Summary

Global Markets Direct's, 'SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014', provides an overview of the SymBio Pharmaceuticals Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SymBio Pharmaceuticals Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of SymBio Pharmaceuticals Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of SymBio Pharmaceuticals Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the SymBio Pharmaceuticals Limited's pipeline products

Reasons to buy

  • Evaluate SymBio Pharmaceuticals Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of SymBio Pharmaceuticals Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the SymBio Pharmaceuticals Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of SymBio Pharmaceuticals Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of SymBio Pharmaceuticals Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of SymBio Pharmaceuticals Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • SymBio Pharmaceuticals Limited Snapshot
    • SymBio Pharmaceuticals Limited Overview
    • Key Information
    • Key Facts
  • SymBio Pharmaceuticals Limited - Research and Development Overview
    • Key Therapeutic Areas
  • SymBio Pharmaceuticals Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • SymBio Pharmaceuticals Limited - Pipeline Products Glance
    • SymBio Pharmaceuticals Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • SymBio Pharmaceuticals Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • SymBio Pharmaceuticals Limited - Drug Profiles
    • bendamustine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rigosertib sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SyB-0702
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • SymBio Pharmaceuticals Limited - Pipeline Analysis
    • SymBio Pharmaceuticals Limited - Pipeline Products by Target
    • SymBio Pharmaceuticals Limited - Pipeline Products by Route of Administration
    • SymBio Pharmaceuticals Limited - Pipeline Products by Molecule Type
    • SymBio Pharmaceuticals Limited - Pipeline Products by Mechanism of Action
  • SymBio Pharmaceuticals Limited - Recent Pipeline Updates
  • SymBio Pharmaceuticals Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • forigerimod
  • SymBio Pharmaceuticals Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • SymBio Pharmaceuticals Limited, Key Information
  • SymBio Pharmaceuticals Limited, Key Facts
  • SymBio Pharmaceuticals Limited - Pipeline by Indication, 2014
  • SymBio Pharmaceuticals Limited - Pipeline by Stage of Development, 2014
  • SymBio Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2014
  • SymBio Pharmaceuticals Limited - Partnered Products in Pipeline, 2014
  • SymBio Pharmaceuticals Limited - Partnered Products/ Combination Treatment Modalities, 2014
  • SymBio Pharmaceuticals Limited - Phase II, 2014
  • SymBio Pharmaceuticals Limited - Phase I, 2014
  • SymBio Pharmaceuticals Limited - Preclinical, 2014
  • SymBio Pharmaceuticals Limited - Pipeline by Target, 2014
  • SymBio Pharmaceuticals Limited - Pipeline by Route of Administration, 2014
  • SymBio Pharmaceuticals Limited - Pipeline by Molecule Type, 2014
  • SymBio Pharmaceuticals Limited - Pipeline Products by Mechanism of Action, 2014
  • SymBio Pharmaceuticals Limited - Recent Pipeline Updates, 2014
  • SymBio Pharmaceuticals Limited - Discontinued Pipeline Products, 2014

List of Figures

  • SymBio Pharmaceuticals Limited - Pipeline by Top 10 Indication, 2014
  • SymBio Pharmaceuticals Limited - Pipeline by Stage of Development, 2014
  • SymBio Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2014
  • SymBio Pharmaceuticals Limited - Partnered Products in Pipeline, 2014
  • SymBio Pharmaceuticals Limited - Pipeline by Top 10 Target, 2014
  • SymBio Pharmaceuticals Limited - Pipeline by Top 10 Route of Administration, 2014
  • SymBio Pharmaceuticals Limited - Pipeline by Top 10 Molecule Type, 2014
  • SymBio Pharmaceuticals Limited - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top